Effect of Complementary Therapy with Purslane in Nonalcoholic Fatty Liver Disease

Phase 3

Recruiting

• Conditions: non alcoholic fatty liver- hepatic steatosis and fibrosis-hydro-ethanolic extract of aerial parts of Purslane.; Fatty (change of) liver, not elsewhere classified; K76.0

• Registration Number: IRCT20211116053073N1
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 January 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 27

Inclusion Criteria

Detection of Hepatic Steatosis by Two-Dimensional Elastography Device
Consent to Enter the Scheme
Fatty Liver Patients with Grade F0 and F1

Exclusion Criteria

Pregnancy and Lactation
Diseases such as: Diabetes, Autoimmune Disorders, Cancer, Liver Failure, Viral Hepatitis History, Liver Surgery and Renal Impairment (GFR <50)
History of Food Allergy to Purslane and Herbal Supplements
Taking Hepatoxic Drugs such as Amiodarone, Sodium Valproate or Methotrexate
Body Mass Index more than 40
Consumption of Alcohol more than 30 grams per day for Men and also Consumption of more than 20 grams per day for Women
History of Bariatric Surgery
Fatty Liver Patients with F2, F3, F4 Grades
Consumption of any Multivitamin Supplement and Antioxidant Compounds such as Vitamins C, E and Herbal Medicines during the Intervention Period

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hepatic steatosis and fibrosis. Timepoint: before and at the end of the study. Method of measurement: Two-dimensional elastography device.